Harmony Biosciences Holdings, Inc. NASDAQ:HRMY

Founder-led company

Harmony Biosciences Holdings stock price today

$36.75
+2.54
+7.46%
Financial Health
0
1
2
3
4
5
6
7
8
9

Harmony Biosciences Holdings stock price monthly change

+1.33%
month

Harmony Biosciences Holdings stock price quarterly change

+1.33%
quarter

Harmony Biosciences Holdings stock price yearly change

+3.73%
year

Harmony Biosciences Holdings key metrics

Market Cap
1.94B
Enterprise value
1.83B
P/E
10.85
EV/Sales
4.18
EV/EBITDA
12.74
Price/Sales
4.30
Price/Book
4.67
PEG ratio
0.02
EPS
2.35
Revenue
617.51M
EBITDA
236.88M
Income
137.70M
Revenue Q/Q
29.79%
Revenue Y/Y
30.92%
Profit margin
41.44%
Oper. margin
27.45%
Gross margin
80.93%
EBIT margin
27.45%
EBITDA margin
38.36%
Sign up &
create your own Smart Feed

Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.

Sign up for free

Harmony Biosciences Holdings stock price history

Harmony Biosciences Holdings stock forecast

Harmony Biosciences Holdings financial statements

Average Price Target
Last Year

$44.5

Potential upside: 21.08%

Based on estimate of 3 analysts
  • Analysts Price target

  • Financials & Ratios estimates

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY): Profit margin
Jun 2023 134.21M 34.3M 25.56%
Sep 2023 160.26M 38.46M 24%
Dec 2023 168.41M 26.60M 15.8%
Mar 2024 154.61M 38.33M 24.79%
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY): Debt to assets
Jun 2023 760183000 275.01M 36.18%
Sep 2023 777766000 296.43M 38.11%
Dec 2023 811448000 344.45M 42.45%
Mar 2024 846985000 331.59M 39.15%
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY): Cash Flow
Jun 2023 37.06M -7.77M -339K
Sep 2023 63.1M -813K -55.09M
Dec 2023 76.66M -36.06M -53.52M
Mar 2024 31.14M -6.18M -3.63M

Harmony Biosciences Holdings alternative data

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY): Employee count
Aug 2023 200
Sep 2023 200
Oct 2023 200
Nov 2023 200
Dec 2023 200
Jan 2024 200
Feb 2024 200
Mar 2024 246
Apr 2024 246
May 2024 246
Jun 2024 246
Jul 2024 246

Harmony Biosciences Holdings other data

78.47% -0.88%
of HRMY is owned by hedge funds
47.80M -269.98K
shares is hold by hedge funds

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY): Insider trades (number of shares)
Period Buy Sel
Mar 2024 0 12173
Transaction Date Insider Security Shares Price per share Total value Source
Option
KAPADIA SANDIP officer: CHIEF FINANCIAL OFFICER
Common Stock 15,000 N/A N/A
Option
KAPADIA SANDIP officer: CHIEF FINANCIAL OFFICER
Restricted Stock Units 15,000 N/A N/A
Option
DIERKS JEFFREY officer: CHIEF COMMERCIAL OFFICER
Common Stock 11,979 $8.22 $98,467
Option
DIERKS JEFFREY officer: CHIEF COMMERCIAL OFFICER
Stock Option 9,644 $8.22 $79,274
Sale
DIERKS JEFFREY officer: CHIEF COMMERCIAL OFFICER
Common Stock 11,979 $32 $383,328
Option
DIERKS JEFFREY officer: CHIEF COMMERCIAL OFFICER
Stock Option 2,335 $8.22 $19,194
Option
DIERKS JEFFREY officer: CHIEF COMMERCIAL OFFICER
Stock Option 94 $8.22 $773
Option
DIERKS JEFFREY officer: CHIEF COMMERCIAL OFFICER
Stock Option 100 $8.22 $822
Option
DIERKS JEFFREY officer: CHIEF COMMERCIAL OFFICER
Common Stock 194 $8.22 $1,595
Sale
DIERKS JEFFREY officer: CHIEF COMMERCIAL OFFICER
Common Stock 194 $32 $6,208
Insider Compensation
Mr. John Charles Jacobs M.B.A. (1967) Pres, Chief Executive Officer & Director
$933,940
Dr. Jeffrey M. Dayno M.D. (1957) Chief Medical Officer $734,250
Mr. Jeffrey Dierks M.B.A. (1971) Chief Commercial Officer
$482,450
Mr. Jeffrey S. Aronin (1968) Founder & Non-Executive Chairman $31,200
Friday, 20 December 2024
accesswire.com
Thursday, 19 December 2024
accesswire.com
Wednesday, 18 December 2024
prnewswire.com
accesswire.com
Tuesday, 17 December 2024
accesswire.com
Monday, 16 December 2024
accesswire.com
Friday, 13 December 2024
accesswire.com
Thursday, 12 December 2024
accesswire.com
Wednesday, 11 December 2024
accesswire.com
Tuesday, 10 December 2024
accesswire.com
Monday, 9 December 2024
accesswire.com
Friday, 6 December 2024
accesswire.com
Thursday, 5 December 2024
accesswire.com
Wednesday, 4 December 2024
accesswire.com
Tuesday, 3 December 2024
prnewswire.com
Friday, 29 November 2024
accesswire.com
Tuesday, 26 November 2024
accesswire.com
Monday, 25 November 2024
accesswire.com
Thursday, 21 November 2024
prnewswire.com
accesswire.com
Wednesday, 20 November 2024
accesswire.com
Tuesday, 19 November 2024
accesswire.com
Monday, 18 November 2024
accesswire.com
Friday, 15 November 2024
accesswire.com
Thursday, 14 November 2024
accesswire.com
Wednesday, 13 November 2024
accesswire.com
Tuesday, 12 November 2024
accesswire.com
Monday, 11 November 2024
seekingalpha.com
accesswire.com
Friday, 8 November 2024
accesswire.com
  • What's the price of Harmony Biosciences Holdings stock today?

    One share of Harmony Biosciences Holdings stock can currently be purchased for approximately $36.75.

  • When is Harmony Biosciences Holdings's next earnings date?

    Unfortunately, Harmony Biosciences Holdings's (HRMY) next earnings date is currently unknown.

  • Does Harmony Biosciences Holdings pay dividends?

    No, Harmony Biosciences Holdings does not pay dividends.

  • How much money does Harmony Biosciences Holdings make?

    Harmony Biosciences Holdings has a market capitalization of 1.94B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 32.93% to 582.02M US dollars.

  • What is Harmony Biosciences Holdings's stock symbol?

    Harmony Biosciences Holdings, Inc. is traded on the NASDAQ under the ticker symbol "HRMY".

  • What is Harmony Biosciences Holdings's primary industry?

    Company operates in the Healthcare sector and Biotechnology industry.

  • How do i buy shares of Harmony Biosciences Holdings?

    Shares of Harmony Biosciences Holdings can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

  • Who are Harmony Biosciences Holdings's key executives?

    Harmony Biosciences Holdings's management team includes the following people:

    • Mr. John Charles Jacobs M.B.A. Pres, Chief Executive Officer & Director(age: 58, pay: $933,940)
    • Dr. Jeffrey M. Dayno M.D. Chief Medical Officer(age: 68, pay: $734,250)
    • Mr. Jeffrey Dierks M.B.A. Chief Commercial Officer(age: 54, pay: $482,450)
    • Mr. Jeffrey S. Aronin Founder & Non-Executive Chairman(age: 57, pay: $31,200)
  • Is Harmony Biosciences Holdings founder-led company?

    Yes, Harmony Biosciences Holdings is a company led by its founder Mr. Jeffrey S. Aronin.

  • How many employees does Harmony Biosciences Holdings have?

    As Jul 2024, Harmony Biosciences Holdings employs 246 workers.

  • When Harmony Biosciences Holdings went public?

    Harmony Biosciences Holdings, Inc. is publicly traded company for more then 5 years since IPO on 19 Aug 2020.

  • What is Harmony Biosciences Holdings's official website?

    The official website for Harmony Biosciences Holdings is harmonybiosciences.com.

  • Where are Harmony Biosciences Holdings's headquarters?

    Harmony Biosciences Holdings is headquartered at 630 West Germantown Pike, Plymouth Meeting, PA.

  • How can i contact Harmony Biosciences Holdings?

    Harmony Biosciences Holdings's mailing address is 630 West Germantown Pike, Plymouth Meeting, PA and company can be reached via phone at +48 45399800.

  • What is Harmony Biosciences Holdings stock forecast & price target?

    Based on 3 Wall Street analysts` predicted price targets for Harmony Biosciences Holdings in the last 12 months, the avarage price target is $44.5. The average price target represents a 21.08% change from the last price of $36.75.

Harmony Biosciences Holdings company profile:

Harmony Biosciences Holdings, Inc.

harmonybiosciences.com
Exchange:

NASDAQ

Full time employees:

246

Industry:

Biotechnology

Sector:

Healthcare

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.

630 West Germantown Pike
Plymouth Meeting, PA 19462

CIK: 0001802665
ISIN: US4131971040
CUSIP: 413197104